Meta-analysis  ||| S:0 E:14 ||| JJ
of  ||| S:14 E:17 ||| IN
medical  ||| S:17 E:25 ||| JJ
and  ||| S:25 E:29 ||| CC
non-medical  ||| S:29 E:41 ||| JJ
treatments  ||| S:41 E:52 ||| NNS
of  ||| S:52 E:55 ||| IN
the  ||| S:55 E:59 ||| DT
prodromal  ||| S:59 E:69 ||| JJ
phase  ||| S:69 E:75 ||| NN
of  ||| S:75 E:78 ||| IN
psychotic  ||| S:78 E:88 ||| JJ
illness  ||| S:88 E:96 ||| NN
in  ||| S:96 E:99 ||| IN
at-risk  ||| S:99 E:107 ||| JJ
mental  ||| S:107 E:114 ||| JJ
states  ||| S:114 E:121 ||| NNS
there  ||| S:121 E:127 ||| EX
are  ||| S:127 E:131 ||| VBP
now  ||| S:131 E:135 ||| RB
many  ||| S:135 E:140 ||| JJ
existing  ||| S:140 E:149 ||| JJ
studies  ||| S:149 E:157 ||| NNS
which  ||| S:157 E:163 ||| WDT
assess  ||| S:163 E:170 ||| VBP
the  ||| S:170 E:174 ||| DT
treatments  ||| S:174 E:185 ||| JJ
available  ||| S:185 E:195 ||| JJ
for  ||| S:195 E:199 ||| IN
' ||| S:199 E:200 ||| ''
at  ||| S:200 E:203 ||| IN
risk  ||| S:203 E:208 ||| NN
mental  ||| S:208 E:215 ||| JJ
states ||| S:215 E:221 ||| NNS
' ||| S:221 E:222 ||| POS
,  ||| S:222 E:224 ||| ,
as  ||| S:224 E:227 ||| IN
patients  ||| S:227 E:236 ||| NNS
who  ||| S:236 E:240 ||| WP
are  ||| S:240 E:244 ||| VBP
believed  ||| S:244 E:253 ||| VBN
to  ||| S:253 E:256 ||| TO
be  ||| S:256 E:259 ||| VB
in  ||| S:259 E:262 ||| IN
the  ||| S:262 E:266 ||| DT
prodromal  ||| S:266 E:276 ||| JJ
phase  ||| S:276 E:282 ||| NN
of  ||| S:282 E:285 ||| IN
psychotic  ||| S:285 E:295 ||| JJ
illness  ||| S:295 E:303 ||| NNS
are  ||| S:303 E:307 ||| VBP
referred  ||| S:307 E:316 ||| VBN
to ||| S:316 E:318 ||| TO
.  ||| S:318 E:320 ||| .
However ||| S:320 E:327 ||| RB
,  ||| S:327 E:329 ||| ,
concerns  ||| S:329 E:338 ||| NNS
regarding  ||| S:338 E:348 ||| VBG
side  ||| S:348 E:353 ||| NN
effects  ||| S:353 E:361 ||| NNS
of  ||| S:361 E:364 ||| IN
possible  ||| S:364 E:373 ||| JJ
treatments  ||| S:373 E:384 ||| NNS
remain ||| S:384 E:390 ||| VBP
.  ||| S:390 E:392 ||| .
We  ||| S:392 E:395 ||| PRP
here  ||| S:395 E:400 ||| RB
conduct  ||| S:400 E:408 ||| VB
a  ||| S:408 E:410 ||| DT
meta-analysis  ||| S:410 E:424 ||| JJ
of  ||| S:424 E:427 ||| IN
the  ||| S:427 E:431 ||| DT
studies  ||| S:431 E:439 ||| NNS
available  ||| S:439 E:449 ||| VBP
up  ||| S:449 E:452 ||| RP
to  ||| S:452 E:455 ||| TO
October  ||| S:455 E:463 ||| NNP
2010 ||| S:463 E:467 ||| CD
.  ||| S:467 E:469 ||| .
The  ||| S:469 E:473 ||| DT
aim  ||| S:473 E:477 ||| NN
of  ||| S:477 E:480 ||| IN
this  ||| S:480 E:485 ||| DT
study  ||| S:485 E:491 ||| NN
is  ||| S:491 E:494 ||| VBZ
to  ||| S:494 E:497 ||| TO
decide  ||| S:497 E:504 ||| VB
what  ||| S:504 E:509 ||| WP
would  ||| S:509 E:515 ||| MD
be  ||| S:515 E:518 ||| VB
the  ||| S:518 E:522 ||| DT
best  ||| S:522 E:527 ||| JJS
treatment  ||| S:527 E:537 ||| NN
for  ||| S:537 E:541 ||| IN
' ||| S:541 E:542 ||| ''
at  ||| S:542 E:545 ||| IN
high  ||| S:545 E:550 ||| JJ
risk  ||| S:550 E:555 ||| NN
patients ||| S:555 E:563 ||| NNS
' ||| S:563 E:564 ||| POS
.  ||| S:564 E:566 ||| .
all  ||| S:566 E:570 ||| PDT
the  ||| S:570 E:574 ||| DT
available  ||| S:574 E:584 ||| JJ
studies  ||| S:584 E:592 ||| NNS
examining  ||| S:592 E:602 ||| VBG
potential  ||| S:602 E:612 ||| JJ
treatments  ||| S:612 E:623 ||| NNS
during  ||| S:623 E:630 ||| IN
the  ||| S:630 E:634 ||| DT
prodromal  ||| S:634 E:644 ||| JJ
phase  ||| S:644 E:650 ||| NN
of  ||| S:650 E:653 ||| IN
psychotic  ||| S:653 E:663 ||| JJ
illness  ||| S:663 E:671 ||| NN
were  ||| S:671 E:676 ||| VBD
collected ||| S:676 E:685 ||| VBN
.  ||| S:685 E:687 ||| .
They  ||| S:687 E:692 ||| PRP
all  ||| S:692 E:696 ||| RB
showed  ||| S:696 E:703 ||| VBD
comparable  ||| S:703 E:714 ||| JJ
efficacy ||| S:714 E:722 ||| NN
,  ||| S:722 E:724 ||| ,
which  ||| S:724 E:730 ||| WDT
reached  ||| S:730 E:738 ||| VBD
statistical  ||| S:738 E:750 ||| JJ
significance ||| S:750 E:762 ||| NN
,  ||| S:762 E:764 ||| ,
excluding  ||| S:764 E:774 ||| VBG
the  ||| S:774 E:778 ||| DT
one  ||| S:778 E:782 ||| CD
study  ||| S:782 E:788 ||| NN
using  ||| S:788 E:794 ||| VBG
olanzapine ||| S:794 E:804 ||| NN
,  ||| S:804 E:806 ||| ,
which  ||| S:806 E:812 ||| WDT
in  ||| S:812 E:815 ||| IN
fact  ||| S:815 E:820 ||| NN
' ||| S:820 E:821 ||| POS
tended  ||| S:821 E:828 ||| NN
towards  ||| S:828 E:836 ||| IN
significance ||| S:836 E:848 ||| NN
' ||| S:848 E:849 ||| POS
.  ||| S:849 E:851 ||| CD
treatments  ||| S:851 E:862 ||| NNS
appear  ||| S:862 E:869 ||| VBP
promising  ||| S:869 E:879 ||| VBG
but  ||| S:879 E:883 ||| CC
a  ||| S:883 E:885 ||| DT
balance  ||| S:885 E:893 ||| NN
needs  ||| S:893 E:899 ||| VBZ
to  ||| S:899 E:902 ||| TO
be  ||| S:902 E:905 ||| VB
kept  ||| S:905 E:910 ||| VBN
between  ||| S:910 E:918 ||| IN
adverse  ||| S:918 E:926 ||| JJ
events  ||| S:926 E:933 ||| NNS
and  ||| S:933 E:937 ||| CC
effectiveness  ||| S:937 E:951 ||| NN
of  ||| S:951 E:954 ||| IN
preventing  ||| S:954 E:965 ||| VBG
psychosis.  ||| S:965 E:976 ||| NN
it  ||| S:976 E:979 ||| PRP
is  ||| S:979 E:982 ||| VBZ
necessary  ||| S:982 E:992 ||| JJ
to  ||| S:992 E:995 ||| TO
search  ||| S:995 E:1002 ||| VB
further  ||| S:1002 E:1010 ||| RBR
for  ||| S:1010 E:1014 ||| IN
treatments  ||| S:1014 E:1025 ||| NNS
in  ||| S:1025 E:1028 ||| IN
order  ||| S:1028 E:1034 ||| NN
to  ||| S:1034 E:1037 ||| TO
identify  ||| S:1037 E:1046 ||| VB
effective  ||| S:1046 E:1056 ||| JJ
treatments  ||| S:1056 E:1067 ||| NNS
with  ||| S:1067 E:1072 ||| IN
fewer  ||| S:1072 E:1078 ||| JJR
adverse  ||| S:1078 E:1086 ||| JJ
side  ||| S:1086 E:1091 ||| NN
effects  ||| S:1091 E:1099 ||| NNS
in  ||| S:1099 E:1102 ||| IN
this  ||| S:1102 E:1107 ||| DT
phase  ||| S:1107 E:1113 ||| NN
of  ||| S:1113 E:1116 ||| IN
psychotic  ||| S:1116 E:1126 ||| JJ
illness ||| S:1126 E:1133 ||| NN
.  ||| S:1133 E:1135 ||| .
